retatrutide triple agonist obesity trial VisualAbstract: reduces body weight by 17.5% in patients with Media Centre | EASD

The effectiveness was superior to both monoagonists and dual agonists

Acknowledgments Figures were created with the BioRender Software ( Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Triglyceride reduction of 28% addresses a major cardiovascular risk factor

One keeps you well within the obese category

Despite the name, they're unregulated herbal supplements with very little evidence that they work for weight loss

This task fell to Lotte Bjerre Knudsen, a pharmaceutical scientist at Novo Nordisk